DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: With upcoming trials of dysferlin dual AAV gene therapy [18] and other possible therapeutics such as calcium regulators [19], chemical chaperones [20] and cholesterol/lipid modulators [9,21] being evaluated as possible treatments for dysferlinopathy and the fact that definitive molecular diagnosis is typically a prerequisite for participation in clinical trials, it is critical to improve our understanding and classification of DYSF VUSs so that more individuals can obtain a definitive diagnosis and be able to participate in clinical trials.